SCHOTT Pharma AG & Co. KGaA

Driving subcutaneous self-injection of large volume doses: SCHOTT Pharma launches large format ready-to-use cartridges for on-body devices

SCHOTT Pharma continues growth path in the second quarter of fiscal year 2024

Expanding prefillable glass syringe output: SCHOTT Pharma opens state-of-the-art production facility in Lukácsháza, Hungary

SCHOTT Pharma confirms outlook for FY 24 based on Q2 results; FY 25 impacted by slower growth from syringes

SCHOTT Pharma AG & Co. KGaA: SCHOTT Pharma see FY 25 impacted by slower growth from syringes

SCHOTT Pharma appoints Tobias Erfurth as Head of Investor Relations

SCHOTT Pharma to Expand in the U.S. with New Prefillable Syringe Manufacturing Facility

Successful 2024 Annual General Meeting of SCHOTT Pharma: Shareholders approve all items on the agenda

SCHOTT Pharma AG & Co. KGaA: Dr. Jens Schulte, sell

SCHOTT Pharma reports good start into fiscal year 2024

SCHOTT Pharma delivers on 2023 targets and continues profitable growth trajectory

SCHOTT Pharma delivers right after IPO with strong profitable growth for the full year, at the upper end of its guidance

Hello SDAX! SCHOTT Pharma reaches next milestone as a publicly listed company

SCHOTT Pharma IPO: Early termination of stabilization period and full exercise of the Greenshoe Option

SCHOTT Pharma AG & Co. KGaA: Andreas Reisse, buy

SCHOTT Pharma AG & Co. KGaA: Ann-Kristin Erkens, buy

SCHOTT Pharma AG & Co. KGaA: Dr. Almuth Steinkühler, buy